2017
Immunotherapy in Lung Cancer
Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematology/Oncology Clinics Of North America 2017, 31: 131-141. PMID: 27912829, DOI: 10.1016/j.hoc.2016.08.004.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced stage non-small cell lung cancerPD-1/PD-L1 axisFirst-line platinum-based doubletStage non-small cell lung cancerApproval of nivolumabPlatinum-based doubletsSecond-line docetaxelGood performance statusImmune checkpoint inhibitorsPD-L1 axisMinority of patientsRandomized clinical trialsTreatment of patientsNew therapeutic approachesClass of drugsCheckpoint inhibitorsOverall survivalPerformance statusClinical trialsProlonged benefitTherapeutic approachesPatients
2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal Of Cancer Research And Clinical Oncology 2008, 135: 467-476. PMID: 18787840, DOI: 10.1007/s00432-008-0466-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiopsyCarcinoma, Non-Small-Cell LungCell DivisionErbB ReceptorsGefitinibGene Expression Regulation, NeoplasticHumansImmunohistochemistryLung NeoplasmsNeoplasm StagingPlacebosPlatinum CompoundsPrognosisQuinazolinesSurvival AnalysisConceptsPlatinum-based chemotherapyCell lung cancerPrognostic factorsLung cancerFirst-line platinum-based chemotherapyEpidermal growth factor receptor stainingChemotherapy-naive patientsPlacebo-controlled trialCox regression analysisReceptor expression analysisStrong prognostic indicatorMembrane stainingEGFR expression correlatesSurvival benefitImproved survivalPrognostic effectGrowth patternPredictive factorsPrognostic indicatorReceptor stainingPoor survivalTreatment groupsEGFR PharmDxEGFR expressionGefitinib
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply